On June 1, 2022 Genomic Testing Cooperative, LCA (GTC) reported that it will be presenting at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2022 annual meeting data showcasing its new innovative approach to liquid biopsy testing that combines both cell-free-DNA (cfDNA) with cell-free RNA (cfRNA), Liquid Trace (Press release, Genomic Testing Cooperative, JUN 1, 2022, View Source [SID1234615349]). Liquid Trace tests both cfDNA and cfRNA not only improves sensitivity of the liquid biopsy but also provides transcriptome data that is enriched by various tumor markers (CA125, CA 15-3, CEA, etc) and makes it possible to perform liquid immunoprofiling by evaluating levels of CD19, CD20, CD33, CD4, CD8, etc.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This data will be presented in two posters:

– "Combining cell-free RNA (cfRNA) with cell-free total nucleic acid (cfTNA) as a new paradigm for liquid biopsy." Abstract # 3048; Poster # 40, Sunday, June 5, 2022, 8:00 AM-11:00 AM CDT

– "Cell-free RNA in liquid biopsy and biomarkers profiling of hematologic and solid tumors."

Abstract # 3047, Poster # 39, Sunday, June 5, 2022, 8:00 AM-11:00 AM CDT

GTC will also present validation data of its innovative artificial Intelligence (AI) approach that uses targeted transcriptome to classify and aid in the differential diagnosis between 47 different diagnoses of hematologic and solid tumors. This AI is particularly powerful in the differential diagnosis between various types of lymphoma and Hodgkin disease and solid tumors of unknown origin. This data will be presented in the following poster:

– "Differential diagnosis of hematologic and solid tumors using targeted transcriptome and artificial intelligence." Abstract # 3018; Poster # 10; Sunday, June 5, 2022, 8:00 AM-11:00 AM CDT; 4:30 PM-6:00 PM (Discussion)

"Our new Liquid Trace test represents a significant leap in the science of liquid biopsy. Cells in various tissues contain the same DNA, but RNA makes the difference between skin and brain tissue. Analyzing RNA is the next step in the advancement of genomics. GTC is committed to combining the science of RNA with AI to bring this type of innovation to everyday practice of molecular testing in tissue biopsy as well as in liquid biopsy," stated Dr. Maher Albitar, founder, chief medical officer, and chief executive officer of GTC. "These advances were possible because of the collaborative (Co-Op) business model that was adapted by GTC. Collaboration between various Co-Op members accelerates innovation and advances genomics. We are grateful for the support and collaborative efforts of various members of the Co-Op"

Visit GTC at booth #4117 at ASCO (Free ASCO Whitepaper) for more details and highlights on this work and on how to become a member of the Co-Op. The abstracts presented at ASCO (Free ASCO Whitepaper) will be made available on GTC’s website after the ASCO (Free ASCO Whitepaper) meeting.

On June 1, 2022 PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, reported that Bharatt Chowrira, Ph.D., J.D., President and Chief Business, Legal & Operating Officer, and Julie Krop, M.D., Chief Medical Officer, will participate in a fireside chat at the Jefferies Healthcare Conference in New York City on Thursday, June 9, 2022, at 9:30am EDT (Press release, PureTech Health, JUN 1, 2022, View Source [SID1234615348]). A webcast of the presentation will be available at View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On June 1, 2022 EXACT Therapeutics AS ("EXACT-Tx", Euronext Growth: EXTX), a clinical-stage biopharmaceutical company with a mission to enhance the therapeutic efficacy of medicines through ultrasound-mediated drug delivery, reported the presentation of preclinical results of Acoustic Cluster Therapy (ACT) in a murine brain model, at the Annual International Symposium for Therapeutic Ultrasound (ISTU) Conference being held on 7th -10th June 2022 in Toronto, Canada (Press release, Exact Therapeutics, JUN 1, 2022, View Source [SID1234615347]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The ISTU is a non-profit organization founded in 2001 to increase and diffuse the knowledge of therapeutic ultrasound to the scientific and medical community and facilitate the translation of therapeutic ultrasound techniques into the clinical area for the benefit of patients worldwide.

The work presented by EXACT-Tx at the ISTU demonstrates the possibility of using ACT to help deliver therapeutics to the brain, addressing a significant unmet medical need with close to 98% of drugs in development unable to cross the blood-brain barrier (BBB).

Dr Masha Strømme, Executive Chair EXACT-Tx said: "These data sets have deepened our understanding of the mechanism behind ACT-induced increased BBB permeability and enhanced accumulation of co-injected molecules, and also given us new insights on the spatial and temporal extravasation pattern induced by ACT, important for understanding the mechanism of this therapeutic strategy for drug delivery to the brain."

On June 1, 2022 ChromaDex Corp. (NASDAQ:CDXC) reported that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presenting virtually at the 12th annual Invitational (Press release, ChromaDex, JUN 1, 2022, View Source [SID1234615345]). This three-day investor conference is expected to feature around 200+ companies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The ChromaDex management team is scheduled to present on Wednesday, June 8th at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) at the Four Seasons Westlake Village.

ChromaDex management will also attend virtual one-on-one meetings with institutional investors throughout the day. For those interested in having a meeting with ChromaDex, please visit www.ldmicro.com for more information.

Webcast link: ChromaDex Investor Presentation – LD Micro Invitational

View ChromaDex’s profile here: View Source

On June 1, 2022 Cambrex, a leading global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle, reported the acquisition of Q1 Scientific – a leading provider of environmentally-controlled cGMP stability storage services for the pharmaceutical, medical device and life science industries, strategically located in Waterford, Ireland (Press release, Cambrex, JUN 1, 2022, View Source [SID1234615344]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Stability storage and testing is a critical component of drug development and commercialization of new therapies. Q1 Scientific brings world-class capabilities to our ever-expanding portfolio of outsourced pharmaceutical services." said Tom Loewald, CEO, Cambrex. "This acquisition is a natural extension of our current offerings that will broaden and increase our expertise in this critical area, as well as our footprint in the European market."

Q1 Scientific’s state-of-the-art cGMP facility is ICH validated to meet the specific storage requirements of any pharmaceutical project, with options from -80 C storage up to +50 C, with a full range of humidity control. The 20,000 sq. ft. Waterford facility boasts nearly 40 walk-in stability storage chambers, reach-in freezers and stability units, and ultra-low temperature freezers for biologic therapies. The company also provides sample management and transport services.

"We’re pleased to join Cambrex as we continue to provide leading stability storage services to our current customers," said Stephen Delaney, CEO, Q1 Scientific. "With Cambrex’s scientific expertise and scale, we’ll be able to accelerate our growth and offer an integrated suite of analytical services, providing a full range of market-leading solutions for our customers."

Cambrex offers a variety of storage and testing capabilities with walk-in and reach-in chambers that meet the ICH Q1A requirements. The acquisition will expand Cambrex’s capabilities into the European market.

As pharmaceutical and biopharmaceutical companies continue to seek outsourcing options for non-core capabilities to reduce their footprint, Q1 Scientific’s stability storage services, combined with Cambrex’s industry-leading analytical services portfolio, provide specialized capabilities of high value to the industry.